Long-term Follow-up from Qualitative Interviews of Patients with Relapsed or Refractory Large B-Cell Lymphoma on Their Treatment Experience While Enrolled in a Lisocabtagene Maraleucel Study

被引：0
|
作者：
Barba, Pere [1 ]
Lanar, Sally [2 ]
Liu, Fei Fei [3 ]
Eliason, Laurie [3 ]
Askew, Kshawna [4 ]
Devlen, Jennifer [5 ]
Furustrand, Ulrika [3 ]
Kostic, Ana [3 ]
机构：
[1] Univ Autonoma Barcelona, Hosp Univ Vall dHebron, Barcelona, Spain
[2] ICON Plc, Lyon, France
[3] Bristol Myers Squibb, Princeton, NJ USA
[4] ICON Plc, Winston Salem, NC USA
[5] ICON Plc, Raleigh, NC USA
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-178858
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Dynamics of Circulating Tumor DNA As a Predictor of Outcomes with Lisocabtagene Maraleucel in Relapsed or Refractory Large B-Cell Lymphoma from the Transcend NHL-001 Study
    Lee, Dasom
    Sworder, Brian J.
    Stepan, Lara
    Okal, Abood
    Huang, Chang-Pin
    Kang, Xiaoman
    Hamilton, James
    Macaulay, Charles
    Olsen, Mari
    Liu, Chih Long
    Diehn, Maximilian
    Peiser, Leanne
    Kurtz, David
    Alizadeh, Ash A.
    BLOOD, 2024, 144 : 3412 - 3412
  • [22] Characteristics of relapsed/refractory diffuse large B-cell lymphoma patients with durable responses to maveropepimut-S, pembrolizumab, and cyclophosphamide: Long-term follow-up from the SPiReL trial
    Pandey, Arjun
    Roos, Kim
    Jiang, Yidi
    Mangoff, Kathryn
    Klein, Gail
    Forward, Nick
    Stewart, Douglas
    Laneuville, Pierre
    Bence-Bruckler, Isabelle
    Mangel, Joy
    Tomlinson, George
    Berinstein, Neil L.
    EJHAEM, 2025, 6 (01):
  • [23] Long-term follow-up of allogeneic stem cell transplantation in relapsed/refractory Hodgkin lymphoma
    Giaccone, L.
    Festuccia, M.
    Zallio, F.
    Sorasio, R.
    Brunello, L.
    Maffini, E.
    Dellacasa, C.
    Passera, R.
    Iovino, G.
    Aydin, S.
    Boccadoro, M.
    Vitolo, U.
    Mordini, N.
    Pini, M.
    Busca, A.
    Bruno, B.
    BONE MARROW TRANSPLANTATION, 2017, 52 (08) : 1208 - 1211
  • [24] Long-term follow-up of allogeneic stem cell transplantation in relapsed/refractory Hodgkin lymphoma
    L Giaccone
    M Festuccia
    F Zallio
    R Sorasio
    L Brunello
    E Maffini
    C Dellacasa
    R Passera
    G Iovino
    S Aydin
    M Boccadoro
    U Vitolo
    N Mordini
    M Pini
    A Busca
    B Bruno
    Bone Marrow Transplantation, 2017, 52 : 1208 - 1211
  • [25] Long-Term Follow-Up of Bridging Therapies Prior to CAR T-Cell Therapy for Relapsed/Refractory Large B Cell Lymphoma
    Ladbury, Colton
    Dandapani, Savita
    Hao, Claire
    Fabros, Mildred
    Amini, Arya
    Sampath, Sagus
    Glaser, Scott
    Sokolov, Karen
    Yeh, Jekwon
    Baird, John H.
    Thiruvengadam, Swetha Kambhampati
    Herrera, Alex
    Mei, Matthew
    Nikolaenko, Liana
    Shouse, Geoffrey
    Budde, Lihua E.
    CANCERS, 2023, 15 (06)
  • [26] Long-term follow-up of paclitaxel and topotecan plus rituximab (TTR) for patients with relapsed and refractory B-cell non-Hodgkin's lymphoma
    Suh, G. K.
    McLaughlin, P.
    Romaguera, J. E.
    Hagemeister, F. B.
    Pro, B.
    Khouri, I. F.
    Samaniego, F.
    Rodriguez, M. A.
    Fayad, L. E.
    Feng, L.
    Younes, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [27] Long-term follow-up of taxol and topotecan plus rituximab (TTR) for patients with relapsed and refractory B-cell non-Hodgkin's lymphoma
    Suh, G.
    Khouri, I.
    McLaughlin, P.
    Romaguera, J.
    Hagemeister, F.
    Pro, B.
    Samaniego, F.
    Rodriguez, M.
    Fayad, L.
    Feng, L.
    Younes, A.
    ANNALS OF ONCOLOGY, 2008, 19 : 149 - 149
  • [28] Comparative efficacy of tisagenlecleucel and lisocabtagene maraleucel among adults with relapsed/refractory large B-cell lymphomas: an indirect treatment comparison
    Schuster, Stephen J.
    Zhang, Jie
    Yang, Hongbo
    Agarwal, Abhijit
    Tang, Wenxi
    Martinez-Prieto, Marcela
    Bollu, Vamsi
    Kuzan, David
    Maziarz, Richard T.
    Kersten, Marie Jose
    LEUKEMIA & LYMPHOMA, 2022, 63 (04) : 845 - 854
  • [29] New drug approval: Lisocabtagene maraleucel for patients with relapsed or refractory diffuse large B-cell lymphoma, primary mediastinal B-cell lymphoma or follicular lymphoma grade 3B after two or more lines of systemic treatment
    Chiche, Edmond
    Loschi, Michael
    BULLETIN DU CANCER, 2022, 109 (09) : 879 - 880
  • [30] Long-term safety for patients with tisagenlecleucel-treated relapsed/refractory diffuse large B-cell lymphoma
    Jaeger, Ulrich
    Tam, Constantine S.
    Borchmann, Peter
    McGuirk, Joseph P.
    Johansen, Marianne
    Waller, Edmund K.
    Jaglowski, Samantha
    Andreadis, Charalambos
    Foley, Stephen R.
    Westin, Jason R.
    Fleury, Isabelle
    Ho, P. Joy
    Mielke, Stephan
    Teshima, Takanori
    Salles, Gilles
    Schuster, Stephen J.
    He, Fiona
    Maziarz, Richard T.
    Mayer, Sebastian
    Makita, Shinichi
    Kersten, Marie J.
    Ghosh, Monalisa
    Wagner-Johnston, Nina
    Kato, Koji
    Corradini, Paolo
    Goto, Hideki
    Colicino, Silvia
    Agarwal, Abhijit
    Lobetti-Bodoni, Chiara
    Bishop, Michael R.
    BLOOD ADVANCES, 2022, 6 (16) : 4816 - 4820
12345